{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T00:19:55Z","timestamp":1768695595683,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with unresectable pancreatic cancer (PC) sometimes experience gastrointestinal bleeding (GIB) due to tumor invasion of the gastrointestinal tract (tumor bleeding); no standard treatment has been established yet for this complication. Palliative radiotherapy (PRT) could be promising, however, there are few reports of PRT for tumor bleeding in patients with unresectable PC. Therefore, we evaluated the outcomes of PRT for tumor bleeding in patients with unresectable PC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We reviewed the medical records of patients with unresectable PC diagnosed at our institution between May 2013 and January 2022, and identified patients with endoscopically confirmed tumor bleeding who had received PRT. PRT was administered at a total dose of 30 Grays (Gy) in 10 fractions, 20\u00a0Gy in 5 fractions, or 8\u00a0Gy in a single fraction, and the dose selection was left to the discretion of the attending radiation oncologists.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>During the study period, 2562 patients were diagnosed as having unresectable PC at our hospital, of which 225 (8.8%) developed GIB. Among the 225 patients, 63 (2.5%) were diagnosed as having tumor bleeding and 20 (0.8%) received PRT. Hemostasis was achieved in 14 of the 20 patients (70%) who received PRT, and none of these patients developed grade 3 or more adverse events related to the PRT. The median time to hemostasis was 8.5\u00a0days (range 7\u201314\u00a0days). The rebleeding rate was 21.4% (3\/14). The median hemoglobin level increased significantly (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) from 5.9 to 9.1\u00a0g\/dL, and the median volume of red blood cell transfusion tended (<jats:italic>p<\/jats:italic>\u2009=\u20090.052) to decrease, from 1120\u00a0mL (range 280\u20133360\u00a0mL) to 280\u00a0mL (range 0\u20135560\u00a0mL) following the PRT. The median overall survival (OS) was 52\u00a0days (95% confidence interval [CI] 39\u2013317). Of the 14 patients in whom hemostasis was achieved following PRT, chemotherapy could be started\/resumed in seven patients (50%), and the median OS in these patients was 260\u00a0days (95% CI 76\u2013not evaluable [NE]). Three patients experienced rebleeding (21.4%), on days 16, 22, and 25, after the start of PRT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study showed that PRT is an effective and safe treatment modality for tumor bleeding in patients with unresectable PC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-023-02367-5","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T09:03:24Z","timestamp":1698743004000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Palliative radiotherapy for tumor bleeding in patients with unresectable pancreatic cancer: a single-center retrospective study"],"prefix":"10.1186","volume":"18","author":[{"given":"Taro","family":"Shibuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhito","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanae","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonao","family":"Taira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Satake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Imaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Mitsunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kento","family":"Tomizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Oyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidehiro","family":"Hojo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,31]]},"reference":[{"issue":"6","key":"2367_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"2367_CR2","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1093\/jjco\/hyv088","volume":"45","author":"MMT Hori","year":"2015","unstructured":"Hori MMT, Shibata A, Katanoda K, Sobue T, Nishimoto H, et al. Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2015;45(9):884\u201391.","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"2367_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1001\/archsurg.2007.17","volume":"143","author":"G Butturini","year":"2008","unstructured":"Butturini G, Stocken DD, Wente MN, Jeekel H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H, Dervenis C, Bassi C, et al. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg. 2008;143(1):75\u201383 (discussion 83).","journal-title":"Arch Surg"},{"issue":"9","key":"2367_CR4","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1177\/2050640620939788","volume":"8","author":"L Aguilera Munoz","year":"2020","unstructured":"Aguilera Munoz L, de Mestier L, Lamallem H, Ja\u00efs B, Maire F, L\u00e9vy P, Rebours V, Hammel P. Gastrointestinal bleeding in patients with pancreatic cancer: causes and haemostatic treatments. United European Gastroenterol J. 2020;8(9):1106\u201314.","journal-title":"United European Gastroenterol J"},{"issue":"4","key":"2367_CR5","doi-asserted-by":"publisher","first-page":"902","DOI":"10.3892\/mco.2015.563","volume":"3","author":"YU Wang","year":"2015","unstructured":"Wang YU, Yuan C, Liu X. Characteristics of gastrointestinal hemorrhage associated with pancreatic cancer: a retrospective review of 246 cases. Mol Clin Oncol. 2015;3(4):902\u20138.","journal-title":"Mol Clin Oncol"},{"issue":"8","key":"2367_CR6","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.6004\/jnccn.2017.0131","volume":"15","author":"MA Tempero","year":"2017","unstructured":"Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB 3rd, Binder E, Cardin DB, Cha C, et al. Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(8):1028\u201361.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"2367_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/BF01658393","volume":"13","author":"H Suzuki","year":"1989","unstructured":"Suzuki H, Miho O, Watanabe Y, Kohyama M, Nagao F. Endoscopic laser therapy in the curative and palliative treatment of upper gastrointestinal cancer. World J Surg. 1989;13(2):158\u201364.","journal-title":"World J Surg"},{"issue":"1","key":"2367_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1055\/s-2007-1012780","volume":"22","author":"EM Mathus-Vliegen","year":"1990","unstructured":"Mathus-Vliegen EM, Tytgat GN. Analysis of failures and complications of neodymium: YAG laser photocoagulation in gastrointestinal tract tumors. A retrospective survey of 18 years\u2019 experience. Endoscopy. 1990;22(1):17\u201323.","journal-title":"Endoscopy"},{"issue":"4","key":"2367_CR9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0016-5107(04)01568-8","volume":"60","author":"DG Adler","year":"2004","unstructured":"Adler DG, Leighton JA, Davila RE, Hirota WK, Jacobson BC, Qureshi WA, Rajan E, Zuckerman MJ, Fanelli RD, Hambrick RD, et al. ASGE guideline: the role of endoscopy in acute non-variceal upper-GI hemorrhage. Gastrointest Endosc. 2004;60(4):497\u2013504.","journal-title":"Gastrointest Endosc"},{"issue":"5","key":"2367_CR10","doi-asserted-by":"publisher","first-page":"W627","DOI":"10.2214\/AJR.10.5148","volume":"196","author":"DI Gwon","year":"2011","unstructured":"Gwon DI, Ko GY, Sung KB, Shin JH, Kim JH, Yoon HK. Endovascular management of extrahepatic artery hemorrhage after pancreatobiliary surgery: clinical features and outcomes of transcatheter arterial embolization and stent-graft placement. AJR Am J Roentgenol. 2011;196(5):W627-634.","journal-title":"AJR Am J Roentgenol"},{"issue":"10","key":"2367_CR11","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1001\/archsurg.143.10.1001","volume":"143","author":"P Limongelli","year":"2008","unstructured":"Limongelli P, Khorsandi SE, Pai M, Jackson JE, Tait P, Tierris J, Habib NA, Williamson RCN, Jiao LR. Management of delayed postoperative hemorrhage after pancreaticoduodenectomy: a meta-analysis. Arch Surg. 2008;143(10):1001\u20137.","journal-title":"Arch Surg"},{"key":"2367_CR12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13014-019-1242-z","volume":"14","author":"LG Sapienza","year":"2019","unstructured":"Sapienza LG, Ning MS, Jhingran A, Lin LL, Leao CR, da Silva BB, Pellizzon ACA, Gomes MJL, Baiocchi G. Short-course palliative radiation therapy leads to excellent bleeding control: a single centre retrospective study. Clin Transl Radiat Oncol. 2019;14:40\u20136.","journal-title":"Clin Transl Radiat Oncol"},{"key":"2367_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12904-015-0034-y","volume":"14","author":"C Kondoh","year":"2015","unstructured":"Kondoh C, Shitara K, Nomura M, Takahari D, Ura T, Tachibana H, Tomita N, Kodaira T, Muro K. Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study. BMC Palliat Care. 2015;14:37.","journal-title":"BMC Palliat Care"},{"issue":"3","key":"2367_CR14","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s005200050242","volume":"7","author":"T Morita","year":"1999","unstructured":"Morita T, Tsunoda J, Inoue S, Chihara S. The Palliative Prognostic Index: a scoring system for survival prediction of terminally ill cancer patients. Support Care Cancer. 1999;7(3):128\u201333.","journal-title":"Support Care Cancer"},{"key":"2367_CR15","doi-asserted-by":"publisher","first-page":"101266","DOI":"10.1016\/j.adro.2023.101266","volume":"8","author":"R Das","year":"2023","unstructured":"Das R, Hadley S, Sahaibbs V, Bednar F, Evans J, Lawrence T, Cuneo K. Predictors of acute and late toxicity in patients receiving chemoradiation for unresectable pancreatic cancer. Adv Radiat Oncol. 2023;8:101266.","journal-title":"Adv Radiat Oncol"},{"issue":"2","key":"2367_CR16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ijrobp.2006.08.070","volume":"67","author":"J Tey","year":"2007","unstructured":"Tey J, Back MF, Shakespeare TP, Mukherjee RK, Lu JJ, Lee KM, Wong LC, Leong CN, Zhu M. The role of palliative radiation therapy in symptomatic locally advanced gastric cancer. Int J Radiat Oncol Biol Phys. 2007;67(2):385\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"2367_CR17","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s00432-009-0553-0","volume":"135","author":"K Hashimoto","year":"2009","unstructured":"Hashimoto K, Mayahara H, Takashima A, Nakajima TE, Kato K, Hamaguchi T, Ito Y, Yamada Y, Kagami Y, Itami J, et al. Palliative radiation therapy for hemorrhage of unresectable gastric cancer: a single institute experience. J Cancer Res Clin Oncol. 2009;135(8):1117\u201323.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"2367_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00432-010-0866-z","volume":"137","author":"H Asakura","year":"2011","unstructured":"Asakura H, Hashimoto T, Harada H, Mizumoto M, Furutani K, Hasuike N, Matsuoka M, Ono H, Boku N, Nishimura T. Palliative radiotherapy for bleeding from advanced gastric cancer: is a schedule of 30 Gy in 10 fractions adequate? J Cancer Res Clin Oncol. 2011;137(1):125\u201330.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"22","key":"2367_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000118","volume":"93","author":"J Tey","year":"2014","unstructured":"Tey J, Choo BA, Leong CN, Loy EY, Wong LC, Lim K, Lu JJ, Koh WY. Clinical outcome of palliative radiotherapy for locally advanced symptomatic gastric cancer in the modern era. Medicine (Baltimore). 2014;93(22): e118.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"2367_CR20","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/02841860701621233","volume":"47","author":"MM Kim","year":"2008","unstructured":"Kim MM, Rana V, Janjan NA, Das P, Phan AT, Delclos ME, Mansfield PF, Ajani JA, Crane CH, Krishnan S. Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol. 2008;47(3):421\u20137.","journal-title":"Acta Oncol"},{"issue":"1","key":"2367_CR21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1186\/s12885-017-3508-x","volume":"17","author":"YH Lee","year":"2017","unstructured":"Lee YH, Lee JW, Jang HS. Palliative external beam radiotherapy for the treatment of tumor bleeding in inoperable advanced gastric cancer. BMC Cancer. 2017;17(1):541.","journal-title":"BMC Cancer"},{"key":"2367_CR22","first-page":"384","volume":"8","author":"CL Chaw","year":"2014","unstructured":"Chaw CL, Niblock PG, Chaw CS, Adamson DJ. The role of palliative radiotherapy for haemostasis in unresectable gastric cancer: a single-institution experience. Ecancermedicalscience. 2014;8:384.","journal-title":"Ecancermedicalscience"}],"updated-by":[{"DOI":"10.1186\/s13014-023-02377-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000}}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02367-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-023-02367-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02367-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T17:03:31Z","timestamp":1702919011000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-023-02367-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,31]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2367"],"URL":"https:\/\/doi.org\/10.1186\/s13014-023-02367-5","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13014-023-02377-3","asserted-by":"object"}]},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,31]]},"assertion":[{"value":"20 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13014-023-02377-3","URL":"https:\/\/doi.org\/10.1186\/s13014-023-02377-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted with the approval of the Institutional Review Board of National Cancer Center Hospital East, Japan (No. 2020-209), and in compliance with the principles laid down in the Declaration of Helsinki. Because this study was a retrospective observational study carried out in Japan, the need to obtain informed consent from the patients was waived by the Institutional Review Board of National Cancer Center Hospital East (No. 2020-209).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MI has received research funding (institution) from AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Chugai, Chiome Bioscience, Delta-Fly Pharma, Eisai, Eli Lilly Japan, Invitae, MSD,J-Pharma, Merck biopharma, Merus N.V., Novartis, Nihon Servier, Ono, Pfizer, and Syneos Health, consulted for AstraZeneca, Chugai, MSD, Nihon Servier, and Novartis, and received speaker honoraria from AbbVie, AstraZeneca, Chugai, Eisai, Eli Lilly Japan, Fujifilm Toyama Chemical, Guardant Health Japan, Incyte Biosciences Japan, MSD, Nihon Servier, Novartis, Nippon Kayaku, Ono, Taisho Pharmaceutical, Teijin, Takeda, Taiho, and Yakult. SM has received research funding from Chugai, Astellas, Toray, Ajinomoto, and Pfizer, and received speaker honoraria from Ono, Toray, and Otsuka. HI has received research funding from Ono, and Novartis, consulted for Nihon Servier, and Kaneka Medix, and received speaker honoraria from Yakult, AstraZeneca, Nihon Servier, Kaneka Medix, Boston Scientific, and SB-Kawasumi Laboratories. MN has received personal fees from AstraZeneca, MSD, Varian Medical Systems, and Illumina outside of the scope of the submitted work. The other authors certify that they have no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"178"}}